Targeting <i>SELPLG/</i>P-selectin glycoprotein ligand 1 in preclinical ARDS: Genetic and epigenetic regulation of the <i>SELPLG</i> promoter.

Pulm Circ · 2023 · PMC9982077 · PMID 36873461

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In this report, we used a novel recombinant tandem PSGL1 immunoglobulin fusion molecule (TSGL‐Ig), a competitive inhibitor of PSGL1/P‐selectin interactions, to demonstrate significant TSGL‐Ig‐mediated decreases in SELPLG lung tissue expression as well as highly significant protection from LPS‐ and VILI‐induced lung injury.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.